Recursion Pharmaceuticals reports Q2 EPS (41c), consensus (35c)

Reports Q2 revenue $19.2M, consensus $15.38M. Had cash, cash equivalents and restricted cash of $533.8M at quarter end. Expects to reduce pro forma operating expenses by 35% from 2024 to 2026. “The power of our platform not only allows us to discover and develop potential new medicines, but also gives us insights on patient populations to target that would be challenging using traditional methods,” said Chris Gibson, Co-Founder and CEO. “In discovery, we’re deploying advanced models like Boltz-2 to rapidly design ligands for high-value targets. State of the art platform capabilities helped us drive our fourth partnered discovery milestone with Sanofi this quarter, reflecting tangible momentum across our joint pipeline. We are leveraging these and other improvements to the Recursion OS to not only accelerate and improve our funnel of new programs, but also execution of later stage programs in our pipeline like RBM39 and CDK7.”